AstraZeneca PLC ADR

Ultomiris offers major market opportunities through its long-acting C5 inhibition, leading to significant patient convenience and compliance with fewer infusions. Rapid conversion from older therapies and expanding regulatory approvals across multiple rare diseases enhance market penetration. Its strong sales growth and expansion into neurology and nephrology further solidify its position.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Sales Forecast and Market Size Analysis - 2034" has

European equities traded in the US as American depositary receipts were moving higher late Thursday

WILMINGTON, Del., May 14, 2026--High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had declined cisplatin-based

Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. (NASDAQ:AZN) to develop specialized biopharma AI agents using its K Pro platform, expanding the companies' existing collaboration in drug discovery and development. The agreement will allow Owkin to build end-to-end AI agents designed to operate within AstraZeneca's internal infrastructure and decision-making workflows. The companies said the tools are intended to support competitive intelligence and p

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

Wondering if AstraZeneca at £137.48 is offering fair value or if the price is running ahead of itself? This article walks through what the current valuation signals might mean for you. The stock is up 3.1% over the past week, while the past month shows a decline of 9.7%, with returns of 1.1% year to date and 37.4% over the last year, 20.9% over three years and 92.6% over five years. Recent headlines around AstraZeneca have focused on its role as a major global pharmaceuticals player, with...